Recently, PARP inhibitors have been investigated not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in BRCA1/2 genes. This evidence concerns the gene BRCA1 and cancer.